Corporate | 22 February 2008 11:46
ECKERT & ZIEGLER Strahlen- und Medizintechnik AG / Change of Personnel
Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Berlin, 22 February 2008. The Supervisory Board of Eckert & Ziegler AG
(ISIN DE 0005659700) has appointed Dr. André Heß to be the third member of
the Executive Board as of 1 March 2008. He will assume directorship of the
radiopharmaceuticals segment with the objective of evolving this segment
into a strong pillar of the group.
Following his studies in chemistry and economic engineering as well as a
research position (wissenschaftlicher Mitarbeiter) at the Humboldt
University in Berlin, André Heß joined what would become Eckert & Ziegler
AG as a radiochemist in 1996, where he directed the development department.
In 1999 he was appointed managing director of Eckert & Ziegler Eurotope
GmbH, which develops and markets radioactive medical implants as well as
the associated production technology on an international scale. Since 2005
he has been in charge of development, production, and sales of innovative
radiopharmaceutical synthesis systems as well as customized development for
radiopharmaceutical production technologies within the radiopharmaceuticals
segment of Eckert & Ziegler AG.
In the words of Supervisory Board Chairman Professor Wolfgang Maennig,
'With the Modular Lab family of synthesis systems, André Heß and his team
have demonstrated over the past years that they can successfully develop
and introduce new products onto the market. It is therefore only logical to
give Mr. Heß greater responsibilities and to make use of his abilities for
the entire segment. We see considerable opportunities for growth in the
radiopharmaceuticals sector for Eckert & Ziegler. With the appointment of
Mr. Heß, we want to ensure that sufficient management capacities are
available for further expansion.'
With more than 370 employees worldwide, Eckert & Ziegler AG is one of the
leading suppliers of radioactive applications in medicine, research, and
industry. The company anticipates sales of approximately 60 million euros
in 2008, of which products from the radiopharmaceuticals segment will
account for around 12 million euros. These include automated synthesis
systems for radiodiagnostics as well as contrast agents for positron
emission tomography (PET).
The Executive Board
For enquiries please contact:
Eckert & Ziegler AG, Thomas Scheuch, Investor Relations
Robert-Rössle-Str. 10, D-13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-139, Fax -112, E-mail: thomas.scheuch@ezag.de,
www.ezag.de
22.02.2008 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: ECKERT & ZIEGLER Strahlen- und Medizintechnik AG
Robert-Rössle-Str. 10
13125 Berlin
Deutschland
Phone: +49 (0)30 941 084-0
Fax: +49 (0)30 941 084-112
E-mail: thomas.scheuch@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Hamburg, Düsseldorf
End of News DGAP News-Service
---------------------------------------------------------------------------